New FDA Warning on Canagliflozin
New FDA Warning on CanagliflozinStudies have linked type 2 diabetes drug to increased risk of foot and leg amputations.
Five advancements in diabetes treatment to watch
Five advancements in diabetes treatment to watchThe healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
Invokamet extended-release approved for diabetesFDA recently approved an expanded use for Invokamet (Janssen): Invokamet XR, an extended-release combination drug to treat type 2 diabetes. The original Invokamet was approved by FDA in 2014.
New kidney warning on popular diabetes drugsSoon after FDA warned about a potential increased risk of foot and leg amputations with the use of the type 2 diabetes medication canagliflozin (Invokana and Invokamet, Janssen Biotech), the agency strengthened the existing warning about the risk of acute kidney injury with Invokana and Invokamet, as well as dapagliflozin (Farxiga and Xigduo XR, AstraZeneca).
FDA issues a new warning about popular diabetes drugFDA approves a new indication, then issues strengthened warning about possible effects.
SGLT2 inhibitors for diabetes may cause ketoacidosis, FDA warnsThe FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.
FDA should pull diabetes drug ads, group saysConsumer advocacy group Public Citizen said this week that the Food and Drug Administration (FDA) must stop direct-to-consumer advertisements that market several “dangerous” diabetes medications for weight loss or blood pressure reduction.
FDA approves first fixed-dose treatment for type 2 diabetesFDA has approved canagliflozin/metformin (Invokamet, Janssen), the first fixed-dose combination in the class of sodium glucose co-transporter 2 (SGLT2) inhibitors for the treatment of adults with type 2 diabetes.
ADA: Canagliflozin may be cost-effective treatment option for type 2 diabetes with diet, exercise: StudiesIn adult patients with type 2 diabetes inadequately controlled on metformin monotherapy—the current standard of treatment— canagliflozin (Invokana) 100 mg and 300 mg reduced relative risk for myocardial infarction (1.6% and 3.0%) and congestive heart failure (2.7% and 4.0%), as compared to sitagliptin 100 mg, according to findings of the health economic simulation analysis presented at the American Diabetes Association (ADA) Scientific Sessions in San Francisco.
FDA drug approvals: January 2014FDA approvals, complete response, fast-track designations, priority review, first-time generic approval